Cargando…
Pickering emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-CTLA4 immune checkpoint antibodies
BACKGROUND: Intratumorous immunotherapy for cancer is currently thriving. The aim of such local strategy is to improve the therapeutic index of these treatments, for higher on-target/on-tumor activity and less on-target/off-tumor adverse events. Strategies allowing for slow release of anti-CTLA4 in...
Autores principales: | Tselikas, Lambros, de Baere, Thierry, Isoardo, Thomas, Susini, Sandrine, Ser-Le Roux, Karine, Polrot, Mélanie, Adam, Julien, Rouanne, Mathieu, Zitvogel, Laurence, Moine, Laurence, Deschamps, Fréderic, Marabelle, Aurélien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307549/ https://www.ncbi.nlm.nih.gov/pubmed/32571995 http://dx.doi.org/10.1136/jitc-2020-000579 |
Ejemplares similares
-
Local and distant response to intratumoral immunotherapy assessed by immunoPET in mice
por: Meyblum, Louis, et al.
Publicado: (2023) -
Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade
por: Ju, Fei, et al.
Publicado: (2022) -
Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors
por: Siu, Lillian, et al.
Publicado: (2020) -
Simple and effective bacterial-based intratumoral cancer immunotherapy
por: Carroll, Christina S E, et al.
Publicado: (2021) -
Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
por: Jiang, Xiaoyi, et al.
Publicado: (2022)